• Contact us
  • Advertise with us
  • Login
Tashi Pharma
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • All
    • EDQM
    • EMA
    • European Commision
    • Health Canada
    • Medsafe
    • MHRA
    • SAHPRA
    • US FDA
    FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

    FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

    Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

    US FDA publishes guidance on Initiation of Voluntary Recalls

    EMA publishes Q & A for Bootstrap methodology for f2 similarity factor

    EMA publishes Q & A on Bootstrap methodology for f2 similarity factor

    US FDA publishes product-specific guidances to facilitate generic drug development

    US FDA publishes product-specific guidances to facilitate generic drug development

    Clinical Trials Regulation comes into effect in the EU

    New Clinical Trials Regulation comes into effect in the EU

    Reflection paper Forecasting demand for medicinal products in the EU_EEA

    EMA publishes reflection paper on forecasting demand for medicinal products in the EU/EEA

    Trending Tags

    • Pharma
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • Clinical
    • bioanalytical
  • Webinar
No Result
View All Result
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • All
    • EDQM
    • EMA
    • European Commision
    • Health Canada
    • Medsafe
    • MHRA
    • SAHPRA
    • US FDA
    FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

    FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

    Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

    US FDA publishes guidance on Initiation of Voluntary Recalls

    EMA publishes Q & A for Bootstrap methodology for f2 similarity factor

    EMA publishes Q & A on Bootstrap methodology for f2 similarity factor

    US FDA publishes product-specific guidances to facilitate generic drug development

    US FDA publishes product-specific guidances to facilitate generic drug development

    Clinical Trials Regulation comes into effect in the EU

    New Clinical Trials Regulation comes into effect in the EU

    Reflection paper Forecasting demand for medicinal products in the EU_EEA

    EMA publishes reflection paper on forecasting demand for medicinal products in the EU/EEA

    Trending Tags

    • Pharma
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • Clinical
    • bioanalytical
  • Webinar
No Result
View All Result
No Result
View All Result
Home Global Pharma News

National Association of Manufacturers, USA Selects Mallinckrodt for Two Prestigious Manufacturing Leadership Awards

Mallinckrodt's Specialty Generics division honored with Collaborative Innovation Leadership Award for its COVID-19 pandemic response -- -- Hobart, New York site honored for fourth consecutive year, recognized for Operational Excellence Leadership in 2021 --

PRN by PRN
March 29, 2021
in Global Pharma News
11 1
0
National Association of Manufacturers, USA Selects Mallinckrodt for Two Prestigious Manufacturing Leadership Awards
8
SHARES
18
VIEWS

Mallinckrodt plc today announced that its Specialty Generics division has been recognized as Manufacturing Leadership Award winners for outstanding achievement in two categories – Collaborative Innovation Leadership and Operational Excellence Leadership – by the National Association of Manufacturers (NAM).

Mallinckrodt Specialty Generics COVID-19 Response Team was selected as a Collaborative Innovation Leadership Award winner for its crossfunctional response to the pandemic. To protect the health and safety of its over1600 employees and ensure patients have access to critical medicines throughout the pandemic, the COVID-19 Response Team’s multifaceted program included: implementation of strict safety protocols at its five US-based manufacturing sites; deployment of non-essential employees to work from home; specialized training in accordance with guidance from the Centers for Disease Control and Prevention (CDC); provisions for COVID-19 in-home testing; governance of strict return-to-site and contingency plans; and ongoing employee communications from site-level management and executive leadership. As a result of these measures, Mallinckrodt Specialty Generics experienced zero pandemic-related delays in the manufacturing and distribution of its finished dose and advanced pharmaceutical ingredient (API) products. This included the company’s successful response to an increased demand for acetaminophen – an important pain reliever for COVID-related symptoms – and other essential medicines during the pandemic. Additionally, amidst PPE shortages at the onset of the pandemic, the organization began manufacturing hand sanitizer for donation to emergency management operations located in regions in which it operates and to all Opioid Treatment Programs across the US in support of their uninterrupted care of opioid use disorder patients.

Winner in the Operational Excellence Leadership category, Mallinckrodt Specialty Generics’ Hobart, NY manufacturing facility was recognized for its Packaging Process Improvement Project. The multi-functional team assembled at the Hobart site sought to make significant improvements to the efficiencies and reliability of its carton-sealing process for all packaging lines. Upon completing the initiative, the process improvements successfully realized a reduction in maintenance time and waste, enhanced safety and reliability of packaging shipped to customers, and improved operator productivity and morale, which resulted in significant cost savings.

“We are extremely honored to receive the NAM’s manufacturing leadership awards which come at a pivotal time when the pandemic has exposed the vital need for our country to maintain a domestic, reliable and safe medical supply chain — particularly for low-cost, generic drugs and APIs,” said Spiro Gavaris, President, Mallinckrodt Specialty Generics. “I am incredibly proud of our COVID-19 Response Team’s collaborative efforts this past year and our Hobart team’s ongoing pursuit of innovative manufacturing solutions. Both award recognitions demonstrate Mallinckrodt Specialty Generics’ commitment to providing patients with access to quality generic medicines and our focus on being a US-based supplier of choice to help protect the national security and health of our nation.”

David Hollingshead, Senior Director of Manufacturing and Site Leader at Hobart said, “We are thrilled that the Hobart site has been honored for the fourth year in a row and, in 2021, has earned the prestigious Manufacturing Leadership Award in the Operational Excellence category. Our packaging process improvement project was a total team effort and testament to the passion, mindsets, and behaviors of all Hobart employees for continuous improvement in the manufacturing and delivery of essential products that our customers — and patients — rely on.”

Tags: Mallinckrodt
Previous Post

Health Product Regulatory Authority of Ireland publishes Guide to Clinical Trials Regulation-National Collaboration Project

Next Post

MHRA issues link for Device Online Registration System in Guidance to Register medical devices to place on the market

PRN

PRN

Related Posts

Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Global Pharma News

Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

by admin
February 23, 2022
NDAs of Sandoz Inc have been acquired by ANI Pharmaceuticals
Global Pharma News

Sandoz launches generic lenalidomide in 19 countries across Europe

by admin
February 20, 2022
Revenue of Pfizer up by 95% for year 2021
Global Pharma News

Revenue of Pfizer up by 95% for year 2021

by admin
February 16, 2022
FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant
Global Pharma News

FDA Authorizes New Monoclonal Antibody that Retains Activity Against Omicron Variant

by admin
February 12, 2022
WHO prequalifies first monoclonal antibody - tocilizumab – to treat COVID-19
Global Pharma News

WHO prequalifies first monoclonal antibody – tocilizumab – to treat COVID-19

by admin
February 12, 2022
Next Post
MHRA issues link for Device Online Registration System in Guidance to Register medical devices to place on the market

MHRA issues link for Device Online Registration System in Guidance to Register medical devices to place on the market

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent News

Zydus to launch Oxemia

Zydus to launch Oxemia (Desidustat) a treatment for Anemia in patients with Chronic Kidney Disease (CKD)

March 7, 2022
FDA Urges Companies to be 'Recall Ready’ to Protect Public Health as Part of Final Guidance for Voluntary Recalls

US FDA Urges Companies to be ’Recall Ready’ to Protect Public Health

March 6, 2022
FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

March 5, 2022
Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

US FDA publishes guidance on Initiation of Voluntary Recalls

March 5, 2022
Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

March 5, 2022

Browse by Category

  • Articles
  • Company Focus
  • EDQM
  • EMA
  • European Commision
  • Global Pharma News
  • Guideline News
  • Health Canada
  • Indian Pharma News
  • Interview
  • Medsafe
  • MHRA
  • SAHPRA
  • US FDA
  • Webinar

Browse by Tags

Abbott Alembic alkem Amgen Amneal AstraZeneca bayer biocon Biogen BioNTech Bristol Myers Squibb cipla covid Daiichi Sankyo drreddy Eli Lilly fda Gilead glenmark gsk Incyte Janssen Jubilant lupin MHRA Moderna Natco Novartis Novavax novo nordisk oncology Panacea Biotech Pfizer pharmacy Pharma News Pharmareg News Remdesivir roche sanofi Sun pharma Teva usfda Vaccine Viatris zydus

Contact us

Address:Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002.
Phone:+91 8511586232, +91 9029066605
Email:author@pharmaregnews.com

Browse by Tag

Abbott Alembic alkem Amgen Amneal AstraZeneca bayer biocon Biogen BioNTech Bristol Myers Squibb cipla covid Daiichi Sankyo drreddy Eli Lilly fda Gilead glenmark gsk Incyte Janssen Jubilant lupin MHRA Moderna Natco Novartis Novavax novo nordisk oncology Panacea Biotech Pfizer pharmacy Pharma News Pharmareg News Remdesivir roche sanofi Sun pharma Teva usfda Vaccine Viatris zydus

Advertise with us

© 2021 - Pharmaregnews.com. Developed by YESWEUS.

No Result
View All Result
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • bioanalytical
    • Clinical
  • Webinar
  • Contact us
  • Advertise with us
  • Login

© 2021 - Pharmaregnews.com. Developed by YESWEUS.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?